zoledronic acid has been researched along with Alopecia Cicatrisata in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Dong, N; Hu, A; Qi, Y; Xiang, S; Xiao, J; Zhang, P; Zou, D | 1 |
| Drumm, C; Grogan, L; Maguire, M; Mullally, W; O'Kane, M; Redmond, M; Woods, G | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC | 1 |
1 trial(s) available for zoledronic acid and Alopecia Cicatrisata
| Article | Year |
|---|---|
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid | 2008 |
3 other study(ies) available for zoledronic acid and Alopecia Cicatrisata
| Article | Year |
|---|---|
Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.
Topics: Algorithms; Alopecia; Bayes Theorem; Bone Neoplasms; Cisplatin; Disease Progression; Humans; Lung Neoplasms; Pain; Spinal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2022 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Erythema; Female; Humans; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Scalp; Telangiectasis; Zoledronic Acid | 2020 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |